ADDF’s Fillit On FDA’s Tough Aducanumab Decision, Advances In Alzheimer’s

The US Food and Drug Administration has a difficult decision to make regarding whether or not to approve Biogen, Inc.’s amyloid-targeting antibody aducanumab, Alzheimer’s Drug Discovery Foundation founding executive director and chief scientific officer Howard Fillit said, but while that is dominating the near-term Alzheimer’s discussion, there’s other progress being made.

Scrip spoke with Fillit about Biogen’s closely watched therapeutic candidate, which is developing in partnership with Eisai Co., Ltd.,...